|
|
 Previous Article | Table of Contents | Next Article 
Rearranged Ig Heavy Chain DNA Is Detectable in Cell-Free Blood Samples of Patients With B-Cell Neoplasia
N. Frickhofen,
E. Müller,
M. Sandherr,
T. Binder,
M. Bangerter,
C. Wiest,
M. Enz, and
H. Heimpel
From the Department of Medicine III, University of Ulm, Ulm, Germany.
Tumor-derived DNA has been shown in various cell-free body fluids. In this study, soluble tumor-derived DNA was analyzed in serum and plasma samples of patients with B-cell malignancies. DNA was extracted from tumor cell specimens as well as serum and plasma samples collected from 110 patients with non-Hodgkin's lymphoma and acute B-precursor lymphoblastic leukemia and was subjected to polymerase chain reaction (PCR) analysis for rearranged immunoglobulin heavy chain DNA. In 54% of serum or plasma samples analyzed at different times before and during treatment, clonal DNA from a rearranged immunoglobulin heavy chain locus was detectable. When examined at diagnosis and before any treatment, clonotypic DNA was found in serum or plasma of 86% of the patients. Serum or plasma from patients with systemic or bulky disease was uniformly PCR positive, whereas clonotypic DNA was also recovered from the serum or plasma from the majority of patients with limited disease stages. Degradation of clonal DNA by nucleases in vitro was shown to be one cause of false-negative PCR results. This technical drawback can be relieved by adding a nuclease inhibitor like EDTA, ie, by using plasma instead of serum for PCR analysis. Treatment of patients with cytotoxic drugs was followed by rapid clearance of DNA from the peripheral blood, suggesting that soluble tumor-derived DNA might be associated with viable and proliferating tumor cells. Follow-up studies showed a close correlation of persisting soluble tumor-derived DNA with resistant disease or early relapse. In summary, these data suggest that tumor-derived DNA can be detected in serum or plasma of the majority of patients with B-cell malignancies and that testing of serum or plasma for tumor-associated DNA may be a novel parameter for monitoring response to treatment.
Blood, Vol. 90 No. 12 (December 15), 1997:
pp. 4953-4960
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Hohaus, M. Giachelia, G. Massini, G. Mansueto, B. Vannata, V. Bozzoli, M. Criscuolo, F. D'Alo, M. Martini, L. M. Larocca, et al.
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas
Ann. Onc.,
August 1, 2009;
20(8):
1408 - 1413.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Rogers, Y. Joe, T. Manshouri, A. Dey, I. Jilani, F. Giles, E. Estey, E. Freireich, M. Keating, H. Kantarjian, et al.
Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia
Blood,
April 1, 2004;
103(7):
2799 - 2801.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Stemmer, M. Beau-Faller, E. Pencreac'h, E. Guerin, A. Schneider, D. Jaqmin, E. Quoix, M.-P. Gaub, and P. Oudet
Use of Magnetic Beads for Plasma Cell-free DNA Extraction: Toward Automation of Plasma DNA Analysis for Molecular Diagnostics
Clin. Chem.,
November 1, 2003;
49(11):
1953 - 1955.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B M Ryan, F Lefort, R McManus, J Daly, P W N Keeling, D G Weir, and D Kelleher
A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up
Mol. Pathol.,
June 1, 2003;
56(3):
172 - 179.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Jung, S. Klotzek, M. Lewandowski, M. Fleischhacker, and K. Jung
Changes in Concentration of DNA in Serum and Plasma during Storage of Blood Samples
Clin. Chem.,
June 1, 2003;
49(6):
1028 - 1029.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B M Ryan, F Lefort, R McManus, J Daly, P W N Keeling, D G Weir, and D Kelleher
A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up
Gut,
January 1, 2003;
52(1):
101 - 108.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Silva, J. Silva, A. Sanchez, J. M. Garcia, G. Dominguez, M. Provencio, L. Sanfrutos, E. Jareno, A. Colas, P. Espana, et al.
Tumor DNA in Plasma at Diagnosis of Breast Cancer Patients Is a Valuable Predictor of Disease-free Survival
Clin. Cancer Res.,
December 1, 2002;
8(12):
3761 - 3766.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Johnson and Y.M. D. Lo
Plasma Nucleic Acids in the Diagnosis and Management of Malignant Disease
Clin. Chem.,
August 1, 2002;
48(8):
1186 - 1193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Silva, F. Bonilla, H. Blons, F. Coulet, and P. Laurent-Puig
Correspondence re: F. Coulet et al., Detection of Plasma Tumor DNA in Head and Neck Squamous Cell Carcinoma by Microsatellite Typing and p53 Mutation Analysis. Cancer Res., 60: 707-709, 2000.
Cancer Res.,
December 1, 2001;
61(23):
8595 - 8596.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Goessl, H. Krause, M. Müller, R. Heicappell, M. Schrader, J. Sachsinger, and K. Miller
Fluorescent Methylation-specific Polymerase Chain Reaction for DNA-based Detection of Prostate Cancer in Bodily Fluids
Cancer Res.,
November 1, 2000;
60(21):
5941 - 5945.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. S. Kopreski, F. A. Benko, D. J. Borys, A. Khan, T. J. McGarrity, and C. D. Gocke
Somatic Mutation Screening: Identification of Individuals Harboring K-ras Mutations With the Use of Plasma DNA
J Natl Cancer Inst,
June 7, 2000;
92(11):
918 - 923.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. M. D. Lo, S.-F. Leung, L. Y. S. Chan, A. T. C. Chan, K.-W. Lo, P. J. Johnson, and D. P. Huang
Kinetics of Plasma Epstein-Barr Virus DNA during Radiation Therapy for Nasopharyngeal Carcinoma
Cancer Res.,
May 1, 2000;
60(9):
2351 - 2355.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
I. H. N. Wong, M. H. L. Ng, D. P. Huang, and J. C. K. Lee
Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications
Blood,
March 15, 2000;
95(6):
1942 - 1949.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Szczepek, K. Seeberger, J. Wizniak, M. J. Mant, A. R. Belch, and L. M. Pilarski
A High Frequency of Circulating B Cells Share Clonotypic Ig Heavy-Chain VDJ Rearrangements With Autologous Bone Marrow Plasma Cells in Multiple Myeloma, as Measured by Single-Cell and In Situ Reverse Transcriptase-Polymerase Chain Reaction
Blood,
October 15, 1998;
92(8):
2844 - 2855.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
